Cargando…
Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
BACKGROUND: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A national expert...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094497/ https://www.ncbi.nlm.nih.gov/pubmed/33947377 http://dx.doi.org/10.1186/s12910-021-00623-5 |